Tag: Reference

Posted on

New Inhalers for Asthma, COPD Launched – Monthly Prescribing Reference


Monthly Prescribing Reference

New Inhalers for Asthma, COPD Launched
Monthly Prescribing Reference
GlaxoSmithKline announced the launch of Arnuity Ellipta (fluticasone furoate inhalation powder) and Incruse Ellipta (umeclidinium bromide inhalation powder). Arnuity Ellipta is an inhaled corticosteroid indicated for the maintenance treatment of asthma …
GSK Expands Portfolio of Asthma/COPD Medicines in U.S.Drug Discovery & Development
GSK Expands Its Portfolio Of Medicines In US To Treat Asthma And COPDRTT News
GSK expands its portfolio of medicines in the US for patients with asthma and …MarketWatch

all 6 news articles »

View full post on asthma – Google News

Posted on

Relative Bioavailability Study of Two Montelukast Sodium (GW483100) 5 Milligrams (mg) Chewable Tablets and One Reference Montelukast Sodium 5 mg Chewable Tablet in Healthy Adult Subjects

Condition:   Respiratory Disorders
Interventions:   Drug: Reference Montelukast;   Drug: Test 1 Montelukast;   Drug: Test 2 Montelukast
Sponsor:   GlaxoSmithKline
Not yet recruiting – verified December 2014

View full post on ClinicalTrials.gov: asthma | received in the last 14 days

Posted on

Is SLIT-Tablet Tx Safe for Asthma Patients with Allergic Rhinitis? – Monthly Prescribing Reference

Is SLIT-Tablet Tx Safe for Asthma Patients with Allergic Rhinitis?
Monthly Prescribing Reference
All subjects had a confirmed diagnosis of grass-pollen-induced AR/C with or without controlled asthma and a history of medication use to treat symptoms of AR/C during the previous pollen season. A total of 3,314 adult patients and 881 pediatric …

View full post on asthma – Google News

Posted on

To Confirm Equivalent Bronchodilator Efficacy of the Test Product Compared to the Reference Product

Condition:   Asthma
Interventions:   Drug: Budesonide/Formoterol Easyhaler 320/9 ug/inhalation 4 inh;   Drug: Budesonide/Formoterol Easyhaler 320/9 ug/inhalation 1 inh;   Drug: Symbicort Turbuhaler 320/9 ug/inhalation 4 inh;   Drug: Symbicort Turbuhaler 320/9 ug/inhalation 1inh;   Drug: Placebo Symbicort Turbuhaler 320/9 ug/inhalation 4 inh;   Drug: Placebo Budesonide/Formoterol Easyhaler 320/9 ug/inhalation 4 inh;   Drug: Placebo Budesonide/Formoterol Easyhaler 320/9 ug/inhalation 1 inh;   Drug: Placebo Symbicort Turbuhaler 320/9 ug/inhalation 1 inh
Sponsor:   Orion Corporation, Orion Pharma
Not yet recruiting – verified December 2014

View full post on ClinicalTrials.gov: asthma | received in the last 14 days

Posted on

Does Umeclidinium Monotherapy Help Asthma Patients Without ICS? – Monthly Prescribing Reference

Does Umeclidinium Monotherapy Help Asthma Patients Without ICS?
Monthly Prescribing Reference
However, no studies have assessed a long-acting muscarinic antagonist in the absence of inhaled corticosteroids (ICS) for asthma patients. A new study in Respiratory Medicine reports on a double-blind, three-period crossover study of 350 asthma …

View full post on asthma – Google News

Posted on

Overweight Children More Likely to Report Worse Asthma Control – Monthly Prescribing Reference


Monthly Prescribing Reference

Overweight Children More Likely to Report Worse Asthma Control
Monthly Prescribing Reference
Children with early-onset asthma who are overweight or obese may mistake exertional dyspnea and esophageal reflux for loss of asthma control, causing them to use more rescue medication. In a study published in the Journal of Allergy and Clinical …
Overweight kids misinterpret asthma symptoms, potentially overuse medicationEurekAlert (press release)
Obese Asthmatics Overuse Rescue MedicationsPharmacy Times
Seven recent developments involving food allergyHealio

all 7 news articles »

View full post on asthma – Google News

Posted on

FDA: Asthma Drug May Increase Risk of CV, Cerebrovascular Events – Monthly Prescribing Reference

FDA: Asthma Drug May Increase Risk of CV, Cerebrovascular Events
Monthly Prescribing Reference
The Food and Drug Administration (FDA) is warning about a slightly increased risk of cardiovascular and cerebrovascular events among patients being treated with Xolair (omalizumab; Genentech and Novartis) for asthma compared to those not treated with …
Xolair (omalizumab): Drug Safety Communication – Slightly Elevated Risk of …EIN News (press release)

all 2 news articles »

View full post on asthma – Google News

Posted on

Positive Results for Reslizumab in Asthma Trials – Monthly Prescribing Reference

Positive Results for Reslizumab in Asthma Trials
Monthly Prescribing Reference
Teva announced positive results from its Phase 3 studies of reslizumab in patients with uncontrolled moderate to severe asthma with elevated eosinophils, treated with standard of care therapies. Reslizumab is an investigational humanized monoclonal …
Teva's Asthma Drug 'Significantly' Improves Lung Function In Phase 3 TrialsNASDAQ

all 7 news articles »

View full post on asthma – Google News